Fabino Enterprises Past Earnings Performance
Past criteria checks 0/6
Fabino Enterprises's earnings have been declining at an average annual rate of -20.4%, while the Pharmaceuticals industry saw earnings growing at 13.6% annually. Revenues have been declining at an average rate of 17.8% per year.
Key information
-20.4%
Earnings growth rate
-70.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -17.8% |
| Return on equity | -0.6% |
| Net Margin | -0.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Fabino Enterprises makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 125 | 0 | 5 | 0 |
| 30 Jun 24 | 168 | 0 | 5 | 0 |
| 31 Mar 24 | 211 | 0 | 5 | 0 |
| 31 Dec 23 | 181 | 1 | 4 | 0 |
| 30 Sep 23 | 152 | 1 | 4 | 0 |
| 30 Jun 23 | 93 | 1 | 4 | 0 |
| 31 Mar 23 | 34 | 0 | 4 | 0 |
| 31 Dec 22 | 33 | 1 | 4 | 0 |
| 30 Sep 22 | 32 | 1 | 5 | 0 |
| 30 Jun 22 | 36 | 0 | 5 | 0 |
| 31 Mar 22 | 42 | 0 | 5 | 0 |
| 31 Mar 21 | 31 | 0 | 3 | 0 |
| 31 Mar 20 | 75 | 1 | 2 | 0 |
| 31 Mar 19 | 28 | 0 | 3 | 0 |
Quality Earnings: 543444 is currently unprofitable.
Growing Profit Margin: 543444 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 543444 is unprofitable, and losses have increased over the past 5 years at a rate of 20.4% per year.
Accelerating Growth: Unable to compare 543444's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 543444 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.1%).
Return on Equity
High ROE: 543444 has a negative Return on Equity (-0.58%), as it is currently unprofitable.